CMS backs down on 'Part D' Rx changes after fierce opposition
This article was originally published in Scrip
Executive Summary
After being bombarded with angry complaints from American seniors, trade groups and members of Congress for much of the past two months, the Centers for Medicare & Medicaid Services (CMS) on 10 March backed down from certain proposals it revealed in January to change the Medicare Part D prescription drug program, including removing the so-called protected status for antidepressants, antipsychotics and immunosuppressants for transplant patients.